Main characteristics of long-term patients with APL by previous treatment arm
| Variables . | Overall (n = 161) . | ATRA plus arsenic trioxide (n = 83) . | ATRA plus chemotherapy (n = 78) . | P value . |
|---|---|---|---|---|
| Age at study entry, y | .450 | |||
| Mean (SD) | 54.2 (14.6) | 53.4 (14.7) | 55.1 (14.5) | |
| Median (IQR) | 55.2 (45.0-66.2) | 53.5 (40.8-66.9) | 55.7 (46.0-66.2) | |
| Sex, n (%) | .875 | |||
| Male | 79 (49.1) | 40 (48.2) | 39 (50.0) | |
| Female | 82 (50.9) | 43 (51.8) | 39 (50.0) | |
| Time since diagnosis, y | .800 | |||
| Mean (SD) | 7.8 (1.6) | 7.9 (1.5) | 7.8 (1.7) | |
| Median (IQR) | 8.0 (6.6-9.1) | 7.8 (6.9-9.2) | 8.1 (6.2-9.1) | |
| Number of comorbidities, n (%) | .311 | |||
| 0 | 35 (21.7) | 18 (21.7) | 17 (21.8) | |
| 1 | 35 (21.7) | 22 (26.5) | 13 (16.7) | |
| ≥2 | 91 (56.6) | 43 (51.8) | 48 (61.5) | |
| Received additional treatment of APL | .089 | |||
| No | 151 (94.4) | 81 (97.6) | 70 (90.9) | |
| Yes | 9 (5.6) | 2 (2.4) | 7 (9.1) | |
| Missing | 1 (.) | 0 (.) | 1 (.) | |
| Most recent RT-PCR PML-RAR alfa test, n (%) | .193 | |||
| Negative | 130 (96.3) | 68 (98.6) | 62 (93.9) | |
| Positive | 5 (3.7) | 1 (1.4) | 4 (6.1) | |
| Missing | 26 (.) | 14 (.) | 12 (.) | |
| Variables at APL diagnosis | ||||
| WBC count, ×109/L | .097 | |||
| Mean (SD) | 2.1 (2.2) | 2.4 (2.5) | 1.8 (1.8) | |
| Median (IQR) | 1.2 (0.8-2.3) | 1.4 (0.9-2.6) | 1.2 (0.7-1.8) | |
| Platelet count, ×109/L | .392 | |||
| Mean (SD) | 50.3 (45.2) | 53.9 (47.0) | 46.6 (43.2) | |
| Median (IQR) | 34.0 (18.0-64.0) | 36.5 (18.0-83.5) | 32.0 (18.0-58.0) | |
| Hemoglobin count, g/dL | .553 | |||
| Mean (SD) | 9.5 (2.1) | 9.7 (2.1) | 9.4 (2.1) | |
| Median (IQR) | 9.2 (8.3-11.0) | 9.2 (8.5-11.1) | 9.2 (8.0-11.0) | |
| Risk level, n (%) | .334 | |||
| Low | 68 (43.3) | 38 (47.5) | 30 (39.0) | |
| Intermediate | 89 (56.7) | 42 (52.5) | 47 (61.0) | |
| Missing | 4 (.) | 3 (.) | 1 (.) |
| Variables . | Overall (n = 161) . | ATRA plus arsenic trioxide (n = 83) . | ATRA plus chemotherapy (n = 78) . | P value . |
|---|---|---|---|---|
| Age at study entry, y | .450 | |||
| Mean (SD) | 54.2 (14.6) | 53.4 (14.7) | 55.1 (14.5) | |
| Median (IQR) | 55.2 (45.0-66.2) | 53.5 (40.8-66.9) | 55.7 (46.0-66.2) | |
| Sex, n (%) | .875 | |||
| Male | 79 (49.1) | 40 (48.2) | 39 (50.0) | |
| Female | 82 (50.9) | 43 (51.8) | 39 (50.0) | |
| Time since diagnosis, y | .800 | |||
| Mean (SD) | 7.8 (1.6) | 7.9 (1.5) | 7.8 (1.7) | |
| Median (IQR) | 8.0 (6.6-9.1) | 7.8 (6.9-9.2) | 8.1 (6.2-9.1) | |
| Number of comorbidities, n (%) | .311 | |||
| 0 | 35 (21.7) | 18 (21.7) | 17 (21.8) | |
| 1 | 35 (21.7) | 22 (26.5) | 13 (16.7) | |
| ≥2 | 91 (56.6) | 43 (51.8) | 48 (61.5) | |
| Received additional treatment of APL | .089 | |||
| No | 151 (94.4) | 81 (97.6) | 70 (90.9) | |
| Yes | 9 (5.6) | 2 (2.4) | 7 (9.1) | |
| Missing | 1 (.) | 0 (.) | 1 (.) | |
| Most recent RT-PCR PML-RAR alfa test, n (%) | .193 | |||
| Negative | 130 (96.3) | 68 (98.6) | 62 (93.9) | |
| Positive | 5 (3.7) | 1 (1.4) | 4 (6.1) | |
| Missing | 26 (.) | 14 (.) | 12 (.) | |
| Variables at APL diagnosis | ||||
| WBC count, ×109/L | .097 | |||
| Mean (SD) | 2.1 (2.2) | 2.4 (2.5) | 1.8 (1.8) | |
| Median (IQR) | 1.2 (0.8-2.3) | 1.4 (0.9-2.6) | 1.2 (0.7-1.8) | |
| Platelet count, ×109/L | .392 | |||
| Mean (SD) | 50.3 (45.2) | 53.9 (47.0) | 46.6 (43.2) | |
| Median (IQR) | 34.0 (18.0-64.0) | 36.5 (18.0-83.5) | 32.0 (18.0-58.0) | |
| Hemoglobin count, g/dL | .553 | |||
| Mean (SD) | 9.5 (2.1) | 9.7 (2.1) | 9.4 (2.1) | |
| Median (IQR) | 9.2 (8.3-11.0) | 9.2 (8.5-11.1) | 9.2 (8.0-11.0) | |
| Risk level, n (%) | .334 | |||
| Low | 68 (43.3) | 38 (47.5) | 30 (39.0) | |
| Intermediate | 89 (56.7) | 42 (52.5) | 47 (61.0) | |
| Missing | 4 (.) | 3 (.) | 1 (.) |
RT-PCR, reverse transcriptase polymerase chain reaction; SD, standard deviation; WBC, white blood cell.